Irubis was founded in September 2017 by Lorenz Sykora-Mirle, Alexander Geißler, and Anja Müller with the goal of automating the process development and manufacturing of biopharmaceuticals. The Munich-based startup has developed its Monipa measurement system to bring biological active ingredients to market faster. This process analytical technology (PAT) improves the process development and manufacturing of biopharmaceuticals.
The plug-and-play system simplifies the automated measurement of metabolites and nutrients during cell cultivation, as well as protein quantity and quality parameters during purification. Process monitoring and control is designed to enable higher yields and better quality, shortening the overall process development time.
Irubis wants to expand team and increase sales
Anja Müller, CEO and co-founder of Irubis, says:
"This seed funding round reinforces our mission to make our Monipa system the state-of-the-art in process monitoring. This funding round will enable us to scale, grow our team, increase revenue, and bring the next product version to market."
And Laura Pedroza, Investment Manager at High-Tech Founders Fund, added:
"Sensitive and robust measurements without additional time-consuming calibration are a long-awaited necessity for biopharmaceutical drug production. Irubis meets this need with its innovative and reliable Monipa technology. Together with our co-investors, we look forward to scaling next year."
